Chronic kidney disease is rising faster than India can build the capacity to treat it. Home haemodialysis is the practical response — and no one yet delivers it as a single-standard national network.
Chronic kidney disease in India is driven by diabetes and hypertension in an ageing, urbanising population. These are long-run trends, not a passing wave. The patient population needing maintenance dialysis grows every year, and each patient needs treatment two or three times a week, often indefinitely.
Building and staffing dialysis centres is slow and capital-heavy. Centres cluster in cities and fill quickly, leaving patients travelling long distances several times a week for a chair that many others also need. The gap between demand and centre capacity widens rather than closes.
For a growing number of families, bringing dialysis into the home removes the travel, the waiting and the exposure of a shared centre — while keeping the patient on the full clinical treatment they need. What does not exist is the infrastructure to deliver it consistently, at scale, to one standard.
In a hospital or centre setting one dialysis machine is shared between many patients, one session after another, all day. That sharing is the route by which blood-borne infection can pass between patients — it is why centres must run rigorous disinfection between every session, and why a lapse carries real consequence.
Home haemodialysis removes that exposure at its source. The machine serves one patient and no one else, in the patient’s own home, and the consumables in the blood path are single-use. The patient is not sitting in a shared treatment room alongside others several times a week. For an immunocompromised patient on maintenance dialysis, this significant reduction in cross-infection risk is one of the strongest clinical arguments for treatment at home — and one of the reasons families choose it.
The white space. No one has built a franchised network that lets established local operators deliver home haemodialysis to a single, documented clinical standard — which is precisely the opportunity a Diagnex partnership occupies.
A limited number of exclusive territories are being allocated for 2026. The operators who move first choose their market.
Territories are exclusive and allocated on a first-serious-applicant basis. Tell us your city and we'll confirm whether it's still available.
Territories are being allocated in this first phase, each reviewed within two working days.